Literature DB >> 16237567

Steroid elimination is coming of age.

Minnie Sarwal.   

Abstract

Steroid elimination is being achieved in organ transplantation. The newer generation of more powerful induction and maintenance immunosuppressants offer a new era of safe and effective steroid avoidance. The advantages of achieving independence from steroids definitely extend to the patient. Recent studies also suggest unexpected immunological benefits for the graft. Randomized studies of steroid avoidance and usage are warranted to confirm safety and efficacy, and to address pharmacokinetic and transcriptional changes as a result of steroid elimination, for optimum dosing and monitoring.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16237567     DOI： 10.1007/s00467-005-2042-2

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  24 in total

1.  Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.

Authors:  Lionel Rostaing; Diego Cantarovich; Georges Mourad; Klemens Budde; Paolo Rigotti; Christophe Mariat; Raimund Margreiter; Luis Capdevilla; Phillippe Lang; Paul Vialtel; Joaquin Ortuño-Mirete; Bernard Charpentier; Christophe Legendre; Jaime Sanchez-Plumed; Federico Oppenheimer; Michele Kessler
Journal:  Transplantation       Date:  2005-04-15       Impact factor: 4.939

2.  Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. United Network for Organ Sharing.

Authors:  M M Sarwal; J M Cecka; M T Millan; O Salvatierra
Journal:  Transplantation       Date:  2000-12-27       Impact factor: 4.939

3.  Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.

Authors:  K Washburn; K V Speeg; R Esterl; F Cigarroa; M Pollack; C Tourtellot; P Maxwell; G Halff
Journal:  Transplantation       Date:  2001-11-27       Impact factor: 4.939

4.  A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under simulect, tacrolimus and sirolimus.

Authors:  E Steve Woodle; Flavio Vincenti; Marc I Lorber; H Albin Gritsch; Donald Hricik; Kenneth Washburn; Arthur J Matas; Michael Gallichio; John Neylan
Journal:  Am J Transplant       Date:  2005-01       Impact factor: 8.086

Review 5.  Steroid-free lymphocyte depletion protocols. The potential for partial tolerance?

Authors:  Jerry McCauley
Journal:  Contrib Nephrol       Date:  2005       Impact factor: 1.580

6.  Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.

Authors:  Olivier Boillot; David A Mayer; Karim Boudjema; Mauro Salizzoni; Bruno Gridelli; Franco Filipponi; Pavel Trunecka; Marek Krawczyk; Pierre-Alain Clavien; Christian Ducerf; Carlos Margarit; Raimund Margreiter; José Mir Pallardo; Krister Hoeckerstedt; George-Phillipe Pageaux
Journal:  Liver Transpl       Date:  2005-01       Impact factor: 5.799

7.  Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients.

Authors:  Neil R Parrott; Abdel Q Hammad; Christopher J E Watson; J Peter A Lodge; Christopher D Andrews
Journal:  Transplantation       Date:  2005-02-15       Impact factor: 4.939

Review 8.  Corticosteroid avoidance in pediatric renal transplantation.

Authors:  Jayakumar R Vidhun; Minnie M Sarwal
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

9.  Long-term immunosuppression, without maintenance prednisone, after kidney transplantation.

Authors:  Arthur J Matas; Raja Kandaswamy; Abhinav Humar; William D Payne; David L Dunn; John S Najarian; Rainer W G Gruessner; Kristen J Gillingham; Lois E McHugh; David E R Sutherland
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

10.  Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.

Authors:  Britta Höcker; Ulrike John; Christian Plank; Elke Wühl; Lutz T Weber; Joachim Misselwitz; Wolfgang Rascher; Otto Mehls; Burkhard Tönshoff
Journal:  Transplantation       Date:  2004-07-27       Impact factor: 4.939
View more
  5 in total

Review 1.  Chronic allograft nephropathy in paediatric renal transplantation.

Authors:  Stephen I Alexander; Jeffrey T Fletcher; Brian Nankivell
Journal:  Pediatr Nephrol       Date:  2006-08-30       Impact factor: 3.714

2.  Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients.

Authors:  Jorge R Ferraris; Titania Pasqualini; Guillermo Alonso; Susana Legal; Patricia Sorroche; Ana M Galich; Héctor Jasper
Journal:  Pediatr Nephrol       Date:  2007-02-09       Impact factor: 3.714

3.  A study on strategies for improving growth and body composition after renal transplantation.

Authors:  Jorge R Ferraris; Titania Pasqualini; Guillermo Alonso; Susana Legal; Patricia Sorroche; Ana Galich; Paula Coccia; Lidia Ghezzi; Verónica Ferraris; Liliana Karabatas; Clara Guida; Héctor Jasper
Journal:  Pediatr Nephrol       Date:  2010-02-12       Impact factor: 3.714

4.  Steroid preservation: the rationale for continued prescribing.

Authors:  Stephen D Marks; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2005-12-31       Impact factor: 3.714

5.  Selective late steroid withdrawal after renal transplantation.

Authors:  Guido F Laube; Jutta Falger; Markus J Kemper; Andrea Zingg-Schenk; Thomas J Neuhaus
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.